A Phase 2/3 interventional study of Tazbentetol and placebo in Amyotrophic Lateral Sclerosis, sponsored by Spinogenix. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Spinogenix · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
This is a Phase 2B/3 adaptive design randomized, double-blind, placebo-controlled (DBPC) study to evaluate the efficacy, safety and tolerability of tazbentetol administered orally in participants with ALS.
The study consists of 2 parts, as follows
Phase 2 double-blind, placebo controlled (DBPC): Randomized, double-blind, placebo-controlled study. Participants will be randomized to receive tazbentetol or placebo for 36 weeks.
Phase 3 double blind, placebo controlled (DBPC): Randomized, double-blind, placebo-controlled study. Participants will be randomized to receive the dose determined from Phase 2 or placebo for 36 weeks.
Open-label extension: Eligible participants who complete 36 weeks in the DBPC of either Phase 2 or Phase 3 will be offered to enroll into the OLE, starting at the corresponding DBPC Week 36 visit, and receive tazbentetol for 36 weeks. The dose for this extension will be based on data from DBPC phases.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
This study's planned enrollment of 430 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Browse Amyotrophic Lateral Sclerosis studies →Spinogenix is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
synthetic small molecule
Drug: Tazbentetol
placebo
Drug: placebo
Participants in both Phase 2B and Phase 3 will be randomized to received study drug tazbentetol or placebo tablets. Participants in the open-label extension phase will receive the dose determined from Phase 2.
Also known as: SPG302
participants in double blind placebo controlled phase will be randomized to received placebo tablets
Phase 2: Absolute change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) total score
Questionnaire administered by a clinician that measures participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Time frame: 36 weeks
Phase 3: Absolute change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) total score
Questionnaire administered by a clinician that measures participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Time frame: 36 weeks
OLE: Absolute change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) total score
Questionnaire administered by a clinician that measures participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Time frame: 36 weeks
Phase 2: Combined Assessment of Function and Survival (CAFS) scores
This assessment ranks clinical outcome based on changes to ALSFRS-R score. A higher score indicates a better clinical outcome.
Time frame: 36 weeks
Phase 2: Change from baseline in Clinician Global Impression-Inhibitory (CGI-I)
Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation
Time frame: 36 weeks
Phase 2: Change from baseline in Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
Questionnaire to assesses cognitive and behavioral changes in people with (ALS) through a 136-point test covering language, verbal fluency, executive function, memory, and visuospatial cognitive domains. A lower score indicates worsening of symptoms.
Time frame: 36 weeks
Phase 2: Change from baseline in ALS Assessment Questionnaire 40 items (ALSAQ-40)
The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. A higher score indicates higher disability.
Time frame: 36 weeks
Phase 2: Change from baseline in Patient Global Impression (PGI) of Improvement
This will measure all aspects of patient health and improvement or decline. A higher scale indicates greater disability.
Time frame: 36 weeks
Phase 2: Change from baseline in Rasch Overall ALS Disability (ROADS).
This will measure patient reported outcomes of overall disability. A lower score indicates greater disability.
Time frame: 36 weeks
Phase 2: Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
This will assess the safety and tolerability of tazbentetol in of participants with ALS
Time frame: 36 weeks
Phase 3: Combined Assessment of Function and Survival (CAFS) scores
This assessment ranks clinical outcome based on changes to ALSFRS-R score. A higher score indicates a better clinical outcome.
Time frame: 36 weeks
Phase 3: Change from baseline in Clinician Global Impression-Inhibitory (CGI-I)
Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation
Time frame: 36 weeks
Phase 3: Change from baseline in Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
Questionnaire to assesses cognitive and behavioral changes in people with (ALS) through a 136-point test covering language, verbal fluency, executive function, memory, and visuospatial cognitive domains. A lower score indicates worsening of symptoms.
Time frame: 36 weeks
Phase 3: Change from baseline in ALS Assessment Questionnaire 40 items (ALSAQ-40)
The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. A higher score indicates higher disability.
Time frame: 36 weeks
Phase 3: Change from baseline in Patient Global Impression (PGI) of Improvement
This will measure all aspects of patient health and improvement or decline. A higher scale indicates greater disability.
Time frame: 36 weeks
Phase 3: Change from baseline in Rasch Overall ALS Disability (ROADS).
This will measure patient reported outcomes of overall disability. A lower score indicates greater disability.
Time frame: 36 weeks
Phase 3: Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
This will assess the safety and tolerability of tazbentetol in of participants with ALS
Time frame: 36 weeks
OLE: Combined Assessment of Function and Survival (CAFS) scores
This assessment ranks clinical outcome based on changes to ALSFRS-R score. A higher score indicates a better clinical outcome.
Time frame: 36 weeks
OLE: Change from baseline in Clinician Global Impression-Inhibitory (CGI-I)
Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation
Time frame: 36 weeks
OLE: Change from baseline in ALS Assessment Questionnaire 40 items (ALSAQ-40)
The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. A higher score indicates higher disability.
Time frame: 36 weeks
OLE: Change from baseline in Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
Questionnaire to assesses cognitive and behavioral changes in people with (ALS) through a 136-point test covering language, verbal fluency, executive function, memory, and visuospatial cognitive domains. A lower score indicates worsening of symptoms.
Time frame: 36 weeks
OLE: Change from baseline in Patient Global Impression (PGI) of Improvement
This will measure all aspects of patient health and improvement or decline. A higher scale indicates greater disability.
Time frame: 36 weeks
OLE: Change from baseline in Rasch Overall ALS Disability (ROADS).
This will measure patient reported outcomes of overall disability. A lower score indicates greater disability.
Time frame: 36 weeks
OLE: Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
This will assess the safety and tolerability of tazbentetol in of participants with ALS
Time frame: 36 weeks
Phase 2: ALSFRS-R total score rate of decline
To further assess the effect of tazbentetol on the progression of ALS
Time frame: 36 weeks
Phase 2: Proportion of patients alive and survival time
To further assess the effect of tazbentetol on the progression of ALS
Time frame: 36 weeks
Phase 2 substudy: To compare electroencephalogram (EEG) outcomes of two dose levels of tazbentetol to placebo in participants with ALS
To measure the change from baseline in EEG delta and power bands at resting state at Weeks 8, 24, and 36
Time frame: 36 weeks
Phase 3: ALSFRS-R total score rate of decline
To further assess the effect of tazbentetol on the progression of ALS
Time frame: 36 weeks
Phase 3: Proportion of patients alive and survival time
To further assess the effect of tazbentetol on the progression of ALS
Time frame: 36 weeks
OLE: ALSFRS-R total score rate of decline
To further assess the effect of tazbentetol on the progression of ALS
Time frame: 36 weeks
OLE: Proportion of patients alive and survival time
To further assess the effect of tazbentetol on the progression of ALS
Time frame: 36 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SPG-302
Amyotrophic Lateral Sclerosis →
Spinogenix